Trial Profile

Investigation about the relationship between systemic sympathetic nerve activity and use of SGLT2 inhibitor in patients with type2 diabetes mellitus.

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Mar 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dapagliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacodynamics

Most Recent Events

04 Mar 2021 Planned End Date changed from 31 Mar 2019 to 31 Mar 2022.
16 Jun 2020 Results (n=15) assessing effects of SGLT2 Inhibitors on Nighttime Sympathetic Nerve Activity in Type 2 Diabetic Patients, presented at the 80th Annual Scientific Sessions of the American Diabetes Association
03 Mar 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com